Skip to main content

Main menu

  • About
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
    • News and Stories
    • Careers
  • Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health
      • Healthy Aging and Mobility
      • Heart Health
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
      • Other Research Focus Areas
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Dilawri Cardiovascular Institute
      • Djavad Mowafaghian Centre for Brain Health
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
    • Research Cores
      • Clinical Trials Platform
      • VCH-VCHRI AI Hub
      • Indigenous Health Research Unit
    • Researcher Directory
    • Events and Workshops
    • Participate in Research
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Research Development
      • Awards and Funding
      • Research Facilitation
      • Grant Management
      • Learning and Development
    • Contracts and Compliance
      • Contract Facilitation at VCHRI
      • Operational Approval
      • Research Privacy
      • Clinical Trials Administration
    • Research Support
      • Communications and Media Relations
      • Financial Policies and Procedures
      • VCH-VCHRI AI Hub
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Clinical Trials
    • Clinical Trials Platform
      • Phase 1 Clinical Trials Research Unit
      • Hematology Research Unit
      • Clinical Research Unit
    • Find a Study
    • Researcher Directory
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Research
  3. Vincent Ho

Vincent Ho

Professor
VCH Clinical Title(s)
Dermatologist
Research Focus
Skin Conditions
Degrees / Designations

MD, FRCPC

Contact Info
vho@interchange.ubc.ca
604-875-5151

Biography

Dr. Vincent Ho is professor at the University of British Columbia (UBC) and head of the Department of Dermatologic Oncology at the British Columbia Cancer Agency. He received his Bachelor of Science in Pharmaceutical Sciences and his MD degree from UBC. After completing his dermatology training at UBC, he obtained postgraduate training in Clinical Pharmacology and Immunodermatology (University of  Michigan) and Cutaneous Oncology (Harvard University).

Dr. Ho’s clinical and research interests include dermatologic therapeutics and oncology, and brings his experience in pharmacology to his research and patients. He has conducted over 60 studies since 1989, and has published extensively: over 80 journal publications, 60 papers presented at conferences, and 11 chapters co-authored in textbooks. As part of his work at the BC Cancer Agency, Dr. Ho is closely involved in cancer prevention campaigns such as the “‘Sun Awareness Week” and “Mole Patrol”.

Research Studies

Psoriasis

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Psoriasis

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis

Psoriasis

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Dermatitis

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

Psoriasis

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Dermatitis

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Psoriasis

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Psoriasis

Chronic Plaque Psoriasis (Ps) Registry

Psoriasis

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • Instagram
  • Bluesky
  • YouTube

© 2026 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy